266 related articles for article (PubMed ID: 35633036)
1. Systemic hormonal contraception and risk of venous thromboembolism.
Heikinheimo O; Toffol E; Partonen T; But A; Latvala A; Haukka J
Acta Obstet Gynecol Scand; 2022 Aug; 101(8):846-855. PubMed ID: 35633036
[TBL] [Abstract][Full Text] [Related]
2. [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].
Plu-Bureau G; Sabbagh E; Hugon-Rodin J
Gynecol Obstet Fertil Senol; 2018 Dec; 46(12):823-833. PubMed ID: 30389542
[TBL] [Abstract][Full Text] [Related]
3. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
4. Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data.
Schink T; Princk C; Braitmaier M; Haug U
BJOG; 2022 Dec; 129(13):2107-2116. PubMed ID: 35876787
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of hormonal contraceptives-related venous thromboembolism.
Hugon-Rodin J; Gompel A; Plu-Bureau G
Eur J Endocrinol; 2014 Dec; 171(6):R221-30. PubMed ID: 25012200
[TBL] [Abstract][Full Text] [Related]
6. Hormonal contraception and risk of venous thromboembolism: national follow-up study.
Lidegaard Ø; Løkkegaard E; Svendsen AL; Agger C
BMJ; 2009 Aug; 339():b2890. PubMed ID: 19679613
[TBL] [Abstract][Full Text] [Related]
7. Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism.
Hugon-Rodin J; Horellou MH; Conard J; Gompel A; Plu-Bureau G
Thromb Haemost; 2018 May; 118(5):922-928. PubMed ID: 29614525
[TBL] [Abstract][Full Text] [Related]
8. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
9. Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen.
Rott H
Hamostaseologie; 2019 Feb; 39(1):42-48. PubMed ID: 30669160
[TBL] [Abstract][Full Text] [Related]
10. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.
Tepper NK; Dragoman MV; Gaffield ME; Curtis KM
Contraception; 2017 Feb; 95(2):130-139. PubMed ID: 27771476
[TBL] [Abstract][Full Text] [Related]
11. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis.
Martínez F; Ramírez I; Pérez-Campos E; Latorre K; Lete I
Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):7-29. PubMed ID: 22239262
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis.
Farris M; Bastianelli C; Rosato E; Brosens I; Benagiano G
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1129-1144. PubMed ID: 28712325
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose.
Oedingen C; Scholz S; Razum O
Thromb Res; 2018 May; 165():68-78. PubMed ID: 29573722
[TBL] [Abstract][Full Text] [Related]
14. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
Carr BR; Ory H
Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
[TBL] [Abstract][Full Text] [Related]
15. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes.
Bergendal A; Persson I; Odeberg J; Sundström A; Holmström M; Schulman S; Björgell O; Kieler H
Obstet Gynecol; 2014 Sep; 124(3):600-609. PubMed ID: 25162263
[TBL] [Abstract][Full Text] [Related]
16. Combined oral contraceptives: venous thrombosis.
de Bastos M; Stegeman BH; Rosendaal FR; Van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010813. PubMed ID: 24590565
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
Farmer RD; Lawrenson RA
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
[TBL] [Abstract][Full Text] [Related]
18. Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.
Ramanadhan S; Hansen K; Henderson JT; Cohen MA; Paynter R; Edelman A
Cochrane Database Syst Rev; 2023 May; 5(5):CD014908. PubMed ID: 37184292
[TBL] [Abstract][Full Text] [Related]
19. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9.
Lidegaard Ø; Nielsen LH; Skovlund CW; Skjeldestad FE; Løkkegaard E
BMJ; 2011 Oct; 343():d6423. PubMed ID: 22027398
[TBL] [Abstract][Full Text] [Related]
20. Comment on 'Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism': author's response.
Bitzer J
J Fam Plann Reprod Health Care; 2013 Oct; 39(4):304-5. PubMed ID: 24062506
[No Abstract] [Full Text] [Related]
[Next] [New Search]
